Despite India’s strong 8.2% GDP growth, markets showed muted reaction as optimism was largely priced in. Geopolitical tensions and trade uncertainties are keeping investors cautious, while a weaker rupee benefits exporters but poses inflation risks. Infrastructure, pharma, and IT services are identified as key sectors to watch.Read More
The Indian rupee has fallen below the significant 90 mark against the U.S. dollar. This marks a continuation of its recent struggles. Weak trade and investment flows are contributing factors. Concerns about a stalled trade deal with Washington are also weighing on the currency. The rupee reached a new all-time low on Wednesday.Read More
Sun Pharma’s subsidiary will invest Rs 3,000 crore in a new manufacturing facility in Madhya Pradesh. The company also launched its innovative drug Ilumya® in India. Despite a premium valuation, technical indicators suggest a generally bullish trend for the stock.Read More
Indian equities opened lower on Wednesday, extending a three-session slide as investors adopted a cautious stance near record highs. Both the Sensex and Nifty edged down, with market sentiment guarded ahead of the Reserve Bank of India’s interest-rate decision and policy cues due Friday.Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.
